id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2016-E-4588-0009,FDA,FDA-2016-E-4588,Letter to U. S. Patent and Trademark Office,Other,Letter(s),2025-11-24T05:00:00Z,2025,11,2025-11-24T05:00:00Z,,2025-11-25T03:03:54Z,,0,0,09000064b9094aca
FDA-2016-E-4588-0008,FDA,FDA-2016-E-4588,Letter to U. S. Patent and Trademark Office,Other,Letter(s),2025-09-19T04:00:00Z,2025,9,2025-09-19T04:00:00Z,,2025-09-19T20:44:23Z,,0,0,09000064b8fb3b25
FDA-2016-E-4588-0006,FDA,FDA-2016-E-4588,Determination of Regulatory Review Period for Purposes of Patent Extension; XTAMPZA ER,Notice,Determinations,2024-12-30T05:00:00Z,2024,12,2024-12-30T05:00:00Z,2025-03-01T04:59:59Z,2025-02-24T02:00:23Z,2024-31023,0,0,0900006486894b77
FDA-2016-E-4588-0005,FDA,FDA-2016-E-4588,Letter to U.S. Patent and Trademark Office,Other,Assessment Document or Analysis,2024-12-19T05:00:00Z,2024,12,2024-12-19T05:00:00Z,,2024-12-19T13:29:15Z,,0,0,090000648687e052
FDA-2016-E-4588-0004,FDA,FDA-2016-E-4588,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2024-03-22T04:00:00Z,2024,3,2024-03-22T04:00:00Z,,2024-03-22T18:21:21Z,,0,0,090000648648d320
FDA-2016-E-4588-0003,FDA,FDA-2016-E-4588,Letter to U S Patent and Trademark Office,Other,Letter(s),2023-10-20T04:00:00Z,2023,10,2023-10-20T04:00:00Z,,2025-11-01T00:44:13Z,,0,0,090000648611305e
FDA-2016-E-4588-0001,FDA,FDA-2016-E-4588,"Patent Extension Application from Cooley LLP (on behalf of Collegium Pharmaceutical, Inc)",Other,Application,2016-12-28T05:00:00Z,2016,12,2016-12-28T05:00:00Z,,2017-07-18T11:56:50Z,,0,0,090000648243b645
FDA-2016-E-4588-0002,FDA,FDA-2016-E-4588,Letter from U.S. Patent and Trademark Office to CDER,Other,Letter(s),2016-12-28T05:00:00Z,2016,12,2016-12-28T05:00:00Z,,2016-12-28T17:45:01Z,,0,0,090000648243b649